Drug
LY2886721
LY2886721 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 83.3%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
83.3%
Based on 5 completed trials
Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_1
6
100%
Phase Distribution
6
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
6(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
83.3%
5 of 6 finished
Non-Completion Rate
16.7%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Terminated(1)
Detailed Status
Completed5
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 1
Trials by Phase
Phase 16 (100.0%)
Trials by Status
completed583%
terminated117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_1
A Safety Study of LY2886721 Single Doses in Healthy Subjects
NCT01133405
completedphase_1
Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants
NCT01367262
completedphase_1
A Study of LY2886721 in Healthy Participants
NCT01534273
completedphase_1
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
NCT01807026
completedphase_1
A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
NCT01227252
Clinical Trials (6)
Showing 6 of 6 trials
NCT01133405Phase 1
A Safety Study of LY2886721 Single Doses in Healthy Subjects
NCT01367262Phase 1
Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants
NCT01534273Phase 1
A Study of LY2886721 in Healthy Participants
NCT01807026Phase 1
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
NCT01227252Phase 1
A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
NCT01561430Phase 1
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6